Stratistics MRC¿¡ µû¸£¸é ¼¼°èÀÇ ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ½ÃÀåÀº 2025³â¿¡ 316¾ï ´Þ·¯¸¦ Â÷ÁöÇÏ¸ç ¿¹Ãø ±â°£ Áß CAGRÀº 14.2%·Î ¼ºÀåÇϸç, 2032³â¿¡´Â 802¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ(RPM)Àº µðÁöÅÐ ±â¼úÀ» Ȱ¿ëÇØ ±âÁ¸ ÀÓ»ó ȯ°æ ¹Û¿¡¼ ȯÀÚÀÇ ÀÇ·á µ¥ÀÌÅ͸¦ ¼öÁýÇÏ´Â ÇコÄɾî´Ù.¿þ¾î·¯ºí, ½º¸¶Æ® ¼¾¼, ¸ð¹ÙÀÏ ¾Û µîÀÇ µð¹ÙÀ̽º°¡ ¹ÙÀÌÅ» »çÀÎ, ¸¸¼ºÁúȯ, Ä¡·á °æ°ú¸¦ ÃßÀûÇÕ´Ï´Ù. ÀÌ µ¥ÀÌÅÍ´Â ÀÇ·á ¼ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿¡°Ô ¾ÈÀüÇÏ°Ô Àü¼ÛµÇ¾î Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µ°ú Àû½Ã¿¡ °³ÀÔÇÒ ¼ö ÀÖ½À´Ï´Ù. RPMÀº ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϰí, º´¿ø ¹æ¹®À» ÁÙÀ̸ç, ƯÈ÷ ÀçÅà ȯ°æ¿¡¼ Àå±âÀûÀÎ Áúº´À» °ü¸®Çϰųª ½Ã¼ú ÈÄ È¸º¹ÇÏ´Â »ç¶÷µéÀÇ Àû±ØÀûÀÎ Ä¡·á¸¦ µ½½À´Ï´Ù.
¸ÞÀÌ¿ä Ŭ¸®´ÐÀÇ COVID-19 ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ÇÁ·Î±×·¥ÀÇ ÈÄÇâÀû ºÐ¼®¿¡ µû¸£¸é RPMÀ» »ç¿ëÇÑ È¯ÀÚÀÇ 30ÀÏ »ç¸Á·üÀº 0.5%ÀÎ ¹Ý¸é, RPMÀ» »ç¿ëÇÏÁö ¾ÊÀº ȯÀÚÀÇ 30ÀÏ »ç¸Á·üÀº 1.7%·Î, ÀÔ¿øÀ²°ú ÁßȯÀÚ½Ç ÀԽǷüµµ À¯ÀÇÇÏ°Ô ³·¾Ò½À´Ï´Ù.
¸¸¼ºÁúȯ ºÎ´ã Áõ°¡¿Í °í·ÉÈ
Àα¸ °í·ÉÈ¿¡ µû¶ó ÀÇ·á ½Ã½ºÅÛÀº Àå±âÀûÀÎ Áúº´À» º¸´Ù È¿À²ÀûÀ¸·Î °ü¸®ÇØ¾ß ÇÒ Çʿ伺ÀÌ ´ëµÎµÇ°í ÀÖ½À´Ï´Ù. ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µÀº ÀçÅÿ¡¼ ½Ç½Ã°£ Ȱ·Â ¡Èĸ¦ ÃßÀûÇϰí ÀÔ¿øÀ» ÁÙÀ̸ç, Ä¡·á ¿¬°è¸¦ °³¼±ÇÏ¿© È®Àå °¡´ÉÇÑ ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ¿þ¾î·¯ºí ±â¼ú°ú ¸ð¹ÙÀÏ Çコ Ç÷§ÆûÀÇ ÅëÇÕÀº Á¢±Ù¼º°ú ȯÀÚ Âü¿©¸¦ ´õ¿í Çâ»ó½Ãŵ´Ï´Ù. ÇÁ·Î¾×Ƽºê Äɾî·ÎÀÇ ÀüȯÀº ÀüÅëÀûÀÎ ÀÇ·á ¼ºñ½º Á¦°ø ¸ðµ¨À» º¯È½Ã۰í ÀÖ½À´Ï´Ù.
ȯÀÚÀÇ µðÁöÅÐ ¸®ÅÍ·¯½Ã ¹× ±â¼ú µµÀÔ ºÎÁ·
°í·ÉÀÇ È¯ÀÚ³ª ³óÃÌÀ̳ª ÀÇ·á ¼ºñ½º°¡ ºÎÁ·ÇÑ Áö¿ªÀÇ È¯ÀÚµéÀº Ä¿³ØÆ¼µå µð¹ÙÀ̽º¸¦ »ç¿ëÇϰųª ¿ø°ÝÀÇ·á Ç÷§ÆûÀ» Ž»öÇÏ´Â µ¥ ¾î·Á¿òÀ» °Þ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ÀÌ·¯ÇÑ µðÁöÅÐ °ÝÂ÷´Â RPM ÇÁ·Î±×·¥ÀÇ È¿°ú¸¦ ÀúÇØÇϰí, »ç¿ë °¡´ÉÇÑ ÅøÀÇ È°¿ë ºÎÁ·À¸·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã ¹× ±â±â »ç¿ë ÆíÀǼº¿¡ ´ëÇÑ ¿ì·Áµµ ȯÀÚµéÀÇ ¸Á¼³ÀÓ¿¡ ÇѸòÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÌ °£±ØÀ» ¸Þ¿ì±â À§Çؼ± ÁýÁßÀûÀÎ ±³À°, °£¼ÒÈµÈ ÀÎÅÍÆäÀ̽º, Á¾ÇÕÀûÀÎ µðÀÚÀÎ Àü·«ÀÌ ÇÊ¿äÇÕ´Ï´Ù.
»õ·Î¿î Ä¡·á ¿µ¿ª ¹× ¿ëµµ·ÎÀÇ È®Àå
¿ø°Ý ¸ð´ÏÅ͸µÀº ´õ ÀÌ»ó ¸¸¼ºÁúȯ °ü¸®¿¡ ±×Ä¡Áö ¾Ê°í, ¼ö¼ú ÈÄ °ü¸®, Á¤½Å°Ç°, °¨¿°º´ ¸ð´ÏÅ͸µÀ¸·Î È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À¼¾¼ ¹× AI ±â¹Ý ºÐ¼®ÀÇ Çõ½ÅÀº RPM ¼Ö·ç¼ÇÀÌ º¸´Ù ±¤¹üÀ§ÇÑ ÀÓ»ó ½Ã³ª¸®¿À¸¦ Áö¿øÇÒ ¼ö ÀÖµµ·Ï Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ½Å°æÇÐÀû ¸Å°³º¯¼ö³ª ÀçȰġ·áÀÇ ÁøÇà»óȲÀ» Áö¼ÓÀûÀ¸·Î ¸ð´ÏÅ͸µÇÏ´Â °ÍÀÌ º´¿ø ¿ÜÀÇ È¯°æ¿¡¼µµ °¡´ÉÇØÁ³½À´Ï´Ù. ÀÌ·¯ÇÑ ´Ù°¢È´Â Àåºñ Á¦Á¶¾÷ü¿Í ¼ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿¡ »õ·Î¿î ¼öÀÔ¿øÀ» Á¦°øÇÏ´Â µ¿½Ã¿¡ Àü¹® ºÐ¾ß Àü¹ÝÀÇ È¯ÀÚ °á°ú¸¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù.
ÀÓ»óÀÇÀÇ µ¥ÀÌÅÍ °úºÎÇÏ¿Í °æ°í ÇǷΰ¨
ÀæÀº °æ°í, ƯÈ÷ ¿À°¨Áö, µÐ°¨È, ´ëÀÀ Áö¿¬ ¶Ç´Â Áß¿äÇÑ À̺¥Æ®ÀÇ ´©¶ôÀ¸·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù. °æ°í ÇǷηΠ¾Ë·ÁÁø ÀÌ Çö»óÀº ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀÇ ½Å·Ú¼ºÀ» ¶³¾î¶ß¸®°í ºÎÀÛ¿ëÀÇ À§ÇèÀ» Áõ°¡½Ãŵ´Ï´Ù. À̸¦ ¿ÏÈÇϱâ À§ÇØ °³¹ßÀÚµéÀº ½Ç¿ëÀûÀÎ °æ°í¿¡ ¿ì¼±¼øÀ§¸¦ µÎ°í ȯÀÚ µ¥ÀÌÅ͸¦ ¹®¸ÆÈÇÏ´Â Áö´ÉÇü ¾Ë°í¸®Áò¿¡ ÁÖ¸ñÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ÀÚµ¿È¿Í ÀÓ»óÀû ÆÇ´ÜÀÇ ±ÕÇüÀ» ¸ÂÃß´Â °ÍÀº ¿©ÀüÈ÷ º¹ÀâÇÑ °úÁ¦ÀÔ´Ï´Ù.
ÆÒµ¥¹ÍÀº RPM µµÀÔÀÇ °è±â°¡ µÇ¾ú°í, ´ë¸é Áø·á¸¦ ÃÖ¼ÒÈÇϰí Ãë¾àÇÑ »ç¶÷µéÀ» º¸È£ÇÏ´Â ¿ªÇÒÀ» °Á¶Çß½À´Ï´Ù. Ãʱ⠰ø±Þ¸ÁÀÇ È¥¶õÀº ÀåºñÀÇ °¡¿ë¼º¿¡ ¿µÇâÀ» ¹ÌÃÆÁö¸¸, ¿ø°ÝÀÇ·á ÀÌ¿ë°ú ¿ø°Ý Áø·áÀÇ ±ÞÁõÀº Àå±âÀûÀÎ ¼ºÀåÀ» °¡¼ÓÇß½À´Ï´Ù. RPMÀº COVID ¾ç¼º ȯÀÚÀÇ ÀçÅà ¸ð´ÏÅ͸µ, ¸¸¼ºÁúȯÀÇ ¿ø°Ý °ü¸®, ÁöÄ£ ÀÇ·á ½Ã½ºÅÛÀ» Áö¿øÇÏ´Â µ¥ ÇʼöÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.
¿¹Ãø ±â°£ Áß Àåºñ ºÎ¹®ÀÌ °¡Àå Ŭ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
µð¹ÙÀ̽º ºÐ¾ß´Â ȯÀÚ µ¥ÀÌÅ͸¦ ¼öÁýÇÏ´Â µ¥ ÀÖÀ¸¸ç, ±âÃÊÀûÀÎ ¿ªÇÒÀ» ÇϹǷΠ¿¹Ãø ±â°£ Áß °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿þ¾î·¯ºí ¼¾¼¿¡¼ À̽ÄÇü ¸ð´ÏÅÍ¿¡ À̸£±â±îÁö ÀÌ·¯ÇÑ ÅøÀº »ý¸®Àû ¸Å°³ º¯¼ö¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù. º´¿ø, ÀçÅÃÀÇ·á, ¿Ü·¡Áø·á ÇöÀå¿¡¼ Æø³Ð°Ô äÅõǰí ÀÖ´Â °ÍÀÌ ±× ¹ü¿ë¼ºÀ» ÀÔÁõÇϰí ÀÖ½À´Ï´Ù. Á¦Á¶¾÷üµéÀº ±â±âÀÇ ¼º´É°ú »ç¿ëÀÚ ÆíÀǼºÀ» ³ôÀ̱â À§ÇØ ¼ÒÇüÈ, ¹èÅ͸® È¿À²¼º, »óÈ£¿î¿ë¼º¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù.
¿¹Ãø ±â°£ Áß Ä¿³ØÆ¼µå/¹«¼± ¸ð´ÏÅ͸µ ºÐ¾ß°¡ °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
¿¹Ãø ±â°£ Áß Ä¿³ØÆ¼µå/¹«¼± ¸ð´ÏÅ͸µ ºÐ¾ß´Â IoT Áö¿ø °Ç° ±â±â ¹× ¸ð¹ÙÀÏ ¿¬°áÀÇ º¸±Þ¿¡ ÈûÀÔ¾î °¡Àå ³ôÀº ¼ºÀå·üÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ·¯ÇÑ ¼Ö·ç¼ÇÀº Ŭ¶ó¿ìµå Ç÷§ÆûÀ¸·ÎÀÇ ¿øÈ°ÇÑ µ¥ÀÌÅÍ Àü¼ÛÀ» °¡´ÉÇÏ°Ô Çϰí, ½Ç½Ã°£ ºÐ¼® ¹× ¿ø°Ý °³ÀÔÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ƯÈ÷ °¡Á¤ ȯ°æ¿¡¼ÀÇ ¹«¼± ½Ã½ºÅÛÀÇ Æí¸®ÇÔÀÌ È¯ÀÚ ¼ö¿ë°ú ÀÇ·á ÇÁ·Î¹ÙÀÌ´õÀÇ Ã¤ÅÃÀ» °¡¼ÓÈÇϰí ÀÖ½À´Ï´Ù.
¿¹Ãø ±â°£ Áß ºÏ¹Ì°¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Âµ¥, À̴ źźÇÑ ÀÇ·á ÀÎÇÁ¶ó¿Í ³ôÀº ¸¸¼ºÁúȯ À¯º´·ü·Î ÀÎÇØ ºÏ¹Ì°¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ±â ¶§¹®ÀÔ´Ï´Ù. ÀÌ Áö¿ªÀº À¯¸®ÇÑ »óȯ Á¤Ã¥, °·ÂÇÑ µðÁöÅÐ Çコ µµÀÔ, RPM ±â¼ú¿¡ ´ëÇÑ Àû±ØÀûÀÎ ÅõÀÚ µîÀÇ ÀÌÁ¡À» ´©¸®°í ÀÖ½À´Ï´Ù. ¹Ì±¹°ú ij³ª´ÙÀÇ ÁÖ¿ä ±â¾÷Àº Àü·«Àû Á¦ÈÞ¿Í Á¦Ç° Ãâ½Ã¸¦ ÅëÇØ ±â¼ú Çõ½ÅÀ» ÃßÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀçÅÃÄ¡·á¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ Àνİú ¼ö¿ä´Â ÀÇ·á ¼ºñ½º Á¦°øÀÇ ÁÖ·ù¿¡¼ RPMÀÇ ¿ªÇÒÀ» °ÈÇϰí ÀÖ½À´Ï´Ù.
¿¹Ãø ±â°£ Áß ºÏ¹Ì´Â ´ÙÀ½°ú °°Àº ÀÌÀ¯·Î °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ Áö¿ªÀº ¿ø°ÝÀÇ·á¿¡ ´ëÇÑ ±ÔÁ¦Àû Áö¿ø°ú ÇÔ²² °¡Ä¡ ±â¹Ý Áø·á¿¡ ÁßÁ¡À» µÎ°í ÀÖÀ¸¸ç, RPMÀÇ ÅëÇÕÀ» °¡¼ÓÈÇϰí ÀÖ½À´Ï´Ù. AI, Ŭ¶ó¿ìµå ÄÄÇ»ÆÃ, ¿þ¾î·¯ºí ±â¼úÀÇ ¹ßÀüÀº ½ÃÀå È®´ë¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á ¼ºñ½º ÇÁ·Î¹ÙÀÌ´õµéÀÌ Áý´Ü°Ç°°ü¸®¸¦ À§ÇÑ È®Àå °¡´ÉÇÑ ¼Ö·ç¼ÇÀ» ã°í ÀÖ´Â °¡¿îµ¥, RPMÀº ÀÌ Áö¿ªÀÇ µðÁöÅÐ Çõ½ÅÀÇ ÇÙ½ÉÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù.
According to Stratistics MRC, the Global Remote Patient Monitoring Market is accounted for $31.6 billion in 2025 and is expected to reach $80.2 billion by 2032 growing at a CAGR of 14.2% during the forecast period. Remote Patient Monitoring (RPM) is a healthcare practice that uses digital technologies to collect medical data from patients outside of traditional clinical settings. Devices such as wearables, smart sensors, and mobile apps track vital signs, chronic conditions, or treatment progress. This data is securely transmitted to healthcare providers for continuous monitoring and timely intervention. RPM improves patient outcomes, reduces hospital visits, and supports proactive care particularly for individuals managing long-term illnesses or recovering from procedures in home-based environments.
According to a retrospective analysis of Mayo Clinic's COVID-19 remote patient monitoring program, engaged patients had a 30-day mortality rate of 0.5% compared to 1.7% for non engaged patients, and showed significantly lower rates of hospitalization and ICU admission.
Rising burden of chronic diseases and aging population
As populations age, healthcare systems are under pressure to manage long-term illnesses more efficiently. Remote patient monitoring offers a scalable solution by enabling real-time tracking of vital signs from home, reducing hospital admissions and improving care coordination. The integration of wearable technologies and mobile health platforms further enhances accessibility and patient engagement. This shift toward proactive care is transforming traditional healthcare delivery models.
Lack of digital literacy and technological adoption among patients
Elderly patients and those in rural or underserved areas often face challenges in using connected devices or navigating telehealth platforms. This digital divide hampers the effectiveness of RPM programs and may lead to underutilization of available tools. Additionally, concerns around data privacy and device usability contribute to hesitation among patients. Bridging this gap requires targeted education, simplified interfaces, and inclusive design strategies.
Expansion into new therapeutic areas and applications
Remote monitoring is no longer confined to chronic disease management it's expanding into post-operative care, mental health, and infectious disease surveillance. Innovations in biosensors and AI-driven analytics are enabling RPM solutions to support a broader range of clinical scenarios. For example, continuous monitoring of neurological parameters or rehabilitation progress is becoming feasible outside hospital settings. This diversification opens new revenue streams for device manufacturers and service providers, while also enhancing patient outcomes across specialties.
Data overload and alert fatigue for clinicians
Frequent alerts especially false positives can lead to desensitization, delayed responses, or missed critical events. This phenomenon, known as alert fatigue, undermines the reliability of monitoring systems and increases the risk of adverse outcomes. To mitigate this, developers are focusing on intelligent algorithms that prioritize actionable alerts and contextualize patient data. However, balancing automation with clinical judgment remains a complex task.
The pandemic acted as a catalyst for RPM adoption, highlighting its role in minimizing in-person visits and safeguarding vulnerable populations. While initial supply chain disruptions affected device availability, the surge in telehealth usage and remote consultations drove long-term growth. RPM became essential for monitoring COVID-positive patients at home, managing chronic conditions remotely, and supporting overwhelmed healthcare systems.
The devices segment is expected to be the largest during the forecast period
The devices segment is expected to account for the largest market share during the forecast period due to its foundational role in capturing patient data. From wearable sensors to implantable monitors, these tools provide continuous insights into physiological parameters. Their widespread adoption across hospitals, home care, and ambulatory settings underscores their versatility. Manufacturers are investing in miniaturization, battery efficiency, and interoperability to enhance device performance and user comfort.
The connected / wireless monitoring segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the connected / wireless monitoring segment is predicted to witness the highest growth rate driven by the proliferation of IoT-enabled health devices and mobile connectivity. These solutions allow seamless data transmission to cloud platforms, enabling real-time analytics and remote interventions. The convenience of wireless systems especially in home settings has accelerated patient acceptance and provider adoption.
During the forecast period, the North America region is expected to hold the largest market share attributed to robust healthcare infrastructure and high chronic disease prevalence. The region benefits from favorable reimbursement policies, strong digital health adoption, and active investment in RPM technologies. Leading players in the U.S. and Canada are driving innovation through strategic collaborations and product launches. Additionally, consumer awareness and demand for home-based care are reinforcing RPM's role in mainstream healthcare delivery.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR owing to The region's emphasis on value-based care, coupled with regulatory support for telehealth, is accelerating RPM integration. Advances in AI, cloud computing, and wearable tech are further propelling market expansion. As healthcare providers seek scalable solutions for population health management, RPM is emerging as a cornerstone of digital transformation in the region.
Key players in the market
Some of the key players in Remote Patient Monitoring Market include Welch Allyn, Vivify Health, Tunstall Healthcare, ResMed Inc., Qardio Inc., Philips Healthcare, Medtronic plc, Masimo Corporation, iRhythm Technologies, Honeywell Life Care Solutions, Health Recovery Solutions, GE HealthCare, Care Innovations, Boston Scientific Corporation, BioTelemetry, AMC Health, AliveCor Inc and Abbott Laboratories
In June 2025, Medtronic announced "MiniMed" as the official name for its upcoming spin-off, the new standalone diabetes care business. This rebranding honors legacy origins and positions the company for focused growth and innovation in diabetes management.
In May 2025, AliveCor launched its flagship AI-powered KardiaMobile 6L Max and introduced KardiaAlert, an advanced ECG monitoring feature for subscribers. This marks its most sophisticated personal ECG system, integrating six-lead AI detection to improve heart rhythm alerts.
In March 2024, Boston Scientific agreed to acquire SoniVie Ltd., a developer of TIVUS(TM) intravascular ultrasound systems for renal denervation. The acquisition enhances the company's interventional cardiology portfolio with novel hypertension treatment devices.